Serving hundreds of leading biopharmaceutical companies globally:

Generated: May 26, 2019

DrugPatentWatch Database Preview

Details for Patent: 7,198,801

« Back to Dashboard

Which drugs does patent 7,198,801 protect, and when does it expire?

Patent 7,198,801 protects ELESTRIN and GELNIQUE 3% and is included in two NDAs.

This patent has fifty-three patent family members in eighteen countries.

Summary for Patent: 7,198,801

Title:	Formulations for transdermal or transmucosal application
Abstract:	The present invention relates generally to formulations for transdermal or transmucosal administration of an active agent. The invention is a substantially malodorous-free and irritation free transdermal formulation which is substantially free of long chain fatty alcohols, long-chain fatty acids, and long-chain fatty esters.
Inventor(s):	Carrara; Dario Norberto R. (Oberwil, CH), Grenier; Arnaud (Steinbrunn le Haut, FR), Besse; Celine (Saint Louis, FR), Simes; Stephen M. (Long Grove, IL), Lehman; Leah M. (Green Oaks, IL)
Assignee:	Antares Pharma IPL AG (Zug, CH)
Application Number:	10/798,161
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 7,198,801
Prior Art and Litigation Support	Order Prior Art and Litigation support for Patent 7,198,801
Patent Claim Types: see list of patent claims	Formulation; Compound; Delivery;

Drugs Protected by US Patent 7,198,801

Subscribe to access the full database, or try a Free Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Mylan Speciality Lp	ELESTRIN	estradiol	GEL, METERED;TRANSDERMAL	021813-001	Dec 15, 2006		RX	Yes	Yes	➤ Sign Up	➤ Sign Up	Y				➤ Sign Up
Allergan Sales Llc	GELNIQUE 3%	oxybutynin	GEL, METERED;TRANSDERMAL	202513-001	Dec 7, 2011		DISCN	Yes	No	➤ Sign Up	➤ Sign Up	Y				➤ Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate

Foreign Priority and PCT Information for Patent: 7,198,801

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
	PCT/EP00/07533	Aug 03, 2000

International Family Members for US Patent 7,198,801

Subscribe to access the full database, or try a Free Trial
Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	030312	➤ Sign Up
Austria	355854	➤ Sign Up
Austria	356636	➤ Sign Up
Austria	485837	➤ Sign Up
Austria	534373	➤ Sign Up
Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

By using our website you are consenting to our use of cookies in accordance with our privacy policy.